Furthermore, the use of PAI-1 inhibitors under IH conditions may also provide insights into the effectiveness of PAI-1 antagonism in preventing or mitigating OSA-mediated CVD. The gene discussed is SERPINE1; the disease is isolated hemihyperplasia.